The Alzheimer-Dementia Panel examines 16 genes associated with an increased risk of developing neurodegenerative conditions: Alzheimer’s disease and genetic disorders that cause dementia. This analysis also includes examination of C9orf72 repeat expansions by repeat-primed PCR (rpPCR), but does not include C9orf72 methylation studies.
Who is this test for?
Patients with a personal and/or family history of Alzheimer’s disease and dementia. Warning signs of these diseases include, but are not limited to: abnormal imaging of the brain, difficultly moving or controlling one’s movement, memory loss that interferes with daily life, changes in mood and personality, difficulty having a conversation or completing familiar tasks, and confusion with the time or place.
What are the potential benefits for my patient?
Patients identified with a disease-causing change (a pathogenic or likely pathogenic variant) in a gene on this panel have an increased risk of developing the associated neurodegenerative disease. Genetic testing may be beneficial in the planning and decision-making process for treatment, psychosocial counseling, and support programs for caregivers and patients. Your patient’s family members can also be tested to help define their risk. If a pathogenic variant is identified in your patient, close relatives (children, siblings, and parents) are up to 50% more likely to also be at increased risk.